Chemomab Therapeutics Stock (NASDAQ: CMMB)

Dernières nouvelles pour Chemomab Therapeutics (NASDAQ:CMMB) Stock

Chemomab Therapeutics

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics Ltd

Demand in the airline sector weakened throughout the first quarter, with expectations of a tough earnings season featuring lower second-quarter forecasts <a target="_blank" href="https://www.benzinga.com/topic/airlines" rel="noreferrer noopener">and reduced 2025 earnings guidance.</a>
Airline stocks are down 24% year-to-date, and BofA Securities analyst Andrew G. Didora notes that demand recovery hinges on achieving macroeconomic stability.
The positive outlook for the airline industry in 2024 was initially based on steady demand, but that has shifted since early February due to factors like macro uncertainty, cuts in DOGE, weaker consumer confidence, poor transborder traffic, stagnating business travel, and slowing transatlantic demand, the analyst writes.
Per Didora, the upcoming first quarter of 2025 earnings season is expected to show weak second-quarter forecasts and lowered 2025 earnings guidance, with analysts adjusting their estimates and price targets.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/travel/25/03/44192357/united-airlines-starlink-rollout-to-boost-regional-aircraft-wi-fi-speed-by-50x" rel="noreferrer noopener">United Airlines&#8217; Starlink Rollout To Boost Regional Aircraft Wi-Fi Speed By 50x</a>
Due to weakening demand and pricing in 1Q25, the airline industry is expected to finish March with pricing at its lowest levels in several quarters.
Airlines need macroeconomic stability for demand to recover and reverse the 24% decline in stock prices year-to-date, the analyst notes.
Here are Didora&#8217;s key takeaways in some of the biggest players in the space:
<ul>
<li>The analyst reiterated the Buy rating on Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), lowering the price forecast from $65 to $56.</li>
<li>Didora maintained the Buy rating on United Airlines Holdings, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>), reducing the price forecast from $110 to $100.</li>
<li>The analyst reiterated the Neutral rating on American Airlines Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>), lowering the price forecast from $16 to $12.</li>
</ul>
The analyst observes that, based on Bank of America&#8217;s aggregated credit and debit card data, spending slowed by 400bps from January to February, and March remained at February&#8217;s levels.
The analyst anticipates that 2025 earnings per share (EPS) forecasts will be at risk, with new projections showing that all airlines are likely to fall short of their full-year earnings targets.
With this trend,&nbsp;Delta Air Lines&#8217; revised 1Q25 unit revenue outlook of -1% suggests March unit revenues could be down 5%, with a forecast of low single-digit declines in 2Q25, assuming a 200bps improvement in April due to the Easter shift.
Specifically, the analyst&#8217;s revised forecasts for Delta and United Airlines are nearly 10% below consensus, at $6.40 and $11.35, respectively.
The analyst observes that while domestic supply has been slow to leave the market, May growth is the lowest in 1H25, aside from January.
Didora projects domestic growth to decrease into 3Q25 as airlines adjust supply to match new demand levels.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44630345/samsungs-china-chip-pivot-gains-steam-with-54-export-surge-amid-us-market-struggles" target="_blank" rel="noreferrer noopener">Samsung&#8217;s China Chip Pivot Gains Steam With 54% Export Surge Amid US Market Struggles</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

News

Price Target

Reiteration

Markets

Analyst Ratings

Trading Ideas

General

Airline Earnings At Risk As Demand Dips Amid Weak Business Travel, Low Transborder Traffic, DOGE Cuts: Analyst Says

<a href="https://www.reuters.com/business/autos-transportation/gm-increase-us-truck-production-following-trumps-tariffs-2025-04-03/" title="https://www.reuters.com/business/autos-transportation/gm-increase-us-truck-production-following-trumps-tariffs-2025-04-03/">https://www.reuters.com/business/autos-transportation/gm-increase-us-truck-production-following-trumps-tariffs-2025-04-03/</a>

Macro Economic Events

Economics

Reuters Earlier Reported 'GM To Increase Truck Production In Indiana Following Trump's Tariffs'

Full Statement:
&#39;We are aware of this report. These were isolated incidents and not reflective of KinderCare&rsquo;s values and the high standards we set for ourselves. In the event that incidents do happen in our centers, we have a strict protocol to promptly notify families and licensing agencies. We also work quickly to resolve issues directly with families by taking accountability and addressing what went wrong. To that end, in each of these referenced incidents, we conducted an investigation and have taken all actions necessary to ensure the safety of the children in our care, including the termination of teachers who were at fault.
Nothing is more important than the health and safety of children in our care. We believe when a parent drops their child off at our programs, they&rsquo;re not simply leaving their little one at a daycare: they&rsquo;re ensuring their child is in a safe, nurturing education program that will support their social, emotional and academic development and give their child confidence for life.
We&rsquo;re proud of our legacy as the nation&rsquo;s leading provider and work hard every day to provide the best possible care for children. Every day at more than 2,500 locations nationwide, our more than 43,000 passionate employees create safe and nurturing environments for more than 200,000 children.
We&rsquo;re proud to be fully licensed and seek voluntary accreditation at all of our programs, demonstrating our commitment to establishing best practices not only for ourselves, but also for the broader child care sector.&#39;

Kindercare Responds To Bear Cave Short Report 'We are aware of this report ... These were isolated incidents and not reflective of KinderCare's values and the high standards we set for ourselves'

Biotech

AMGN

FDA Approves Amgen's UPLINZA As First And Only Treatment For Immunoglobulin G4-Related Disease

L3Harris Delivers First Missionized Skyraider II Aircraft To Support U.S. Air Force Special Operations Command

WF International Limited Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WXM#NASDAQ">WXM</a>) shares are trading lower Thursday on <a href="https://www.benzinga.com/pressreleases/25/04/g44617931/wf-international-limited-announces-closing-of-initial-public-offering">continued IPO volatility</a>. 
What To Know: WF International announced the closing of its IPO of 1.4 million ordinary shares for $4 per share. 
The Chengdu-based company, which provides electromechanical solutions including HVAC and water purification systems, said it raised $5.6 million in gross proceeds from the IPO.
The company made its public debut on the Nasdaq Capital Market this week, but the stock has trended lower since. The sharp decline may suggest a lack of strong demand. It&#8217;s also worth noting that broader markets are facing heavy selling pressure Thursday following reciprocal tariffs from the Trump administration.
WF International said it granted the underwriters a 30-day option to purchase an additional 210,000 shares at the offering price. The Benchmark Company and Axiom Capital Management acted as joint book-running managers.
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44593007/newsmax-stock-soars-more-than-100-as-ipo-momentum-continues-whats-going-on">Newsmax Stock Soars More Than 100% As IPO Momentum Continues: What&#8217;s Going On?</a>
WXM Price Action: WF International shares were down 24.1% at $2.17 at the time of publication, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2'">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403"><img loading="lazy" decoding="async" width="1024" height="531" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03140214/Screenshot-2025-04-03-at-14.01.53-1024x531.png" alt="" class="wp-image-856175" style="width:411px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03140214/Screenshot-2025-04-03-at-14.01.53-1024x531.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03140214/Screenshot-2025-04-03-at-14.01.53-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03140214/Screenshot-2025-04-03-at-14.01.53-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03140214/Screenshot-2025-04-03-at-14.01.53.png 1517w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44631916/wall-street-wipes-out-2-trillion-apple-eyes-worst-day-since-covid-19-pandemic-oil-plummets-whats-driving-markets-thursday">Wall Street Wipes Out $2 Trillion, Apple Eyes Worst Day Since COVID-19 Pandemic, Oil Plummets: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

Movers

WF International Stock Continues To Fall: What's Going On?

Government

Regulations

Politics

Asked If There Are Concerns That China Will Cut Off Supplies Of Pharmaceuticals, White House's Hassett Says Don't Think People Need To Be Worried About That

NBA Hall-of-Famer Earvin "Magic" Johnson is one of the rare athletes who can legitimately claim to be a better businessman than he was as a player. It may come as a surprise, but Johnson believes that thinking about helping other people was one of the keys to building his multi-billion-dollar business empire.
The<a href="https://247wallst.com/personal-finance/2025/03/10/magic-johnson-is-worth-billions-and-says-if-you-want-to-build-wealth-you-cant-just-think-about-your-own-pockets/"> 24/7 Wallstreet</a> website quoted an interview from 2008 where Johnson said, "It&#8217;s easier to build wealth if you think about others instead of only focusing on filling your own pockets." Although that advice sounds counterintuitive, Johnson's logic becomes clear when you look at his business career in its entirety. One of Magic's first and most public forays into the business came when his adopted hometown needed him more than ever.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
It was 1995, four years after Johnson had announced his first retirement from the NBA due to having contracted HIV. The South-Central community of Los Angeles was trying to rebuild after the devastation caused by the rioting that broke out after the Rodney King verdict. The riots, which did hundreds of millions of dollars in damage to the community, had essentially scared off the major private investors needed for a rebuild of that scale.
Johnson, who made an estimated $40 million during his playing career, had always dreamed of becoming a businessman. He also had a deep desire to help rebuild the community. In South Central, Johnson saw an opportunity. Johnson stepped into the fray by opening the Magic Johnson Crenshaw 15 movie theaters in the Baldwin Hills Mall on Crenshaw Boulevard in South Central.
Trending: <a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a>
However, Johnson didn't open just any movie theater. He opened up a first-class operation that featured stadium-style seating, multiple concession stands, and state-of-the-art surround sound technology. Those features were commonplace in suburban theaters, but they were virtually absent in South L.A. or any of America's historically underserved communities.
It was a big risk, but it paid off brilliantly for Johnson. Soon, Johnson's chain expanded to Harlem and other minority communities nationwide. Their success was pivotal in convincing big-box stores and retailers like Old Navy that investing in minority neighborhoods could be just as profitable as opening in the suburbs. Johnson, who had a contact list full of top-tier business connections, wasn't done.
See Also: This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a>
In 1998, Johnson convinced Starbucks (NASDAQ:<a href="https://www.benzinga.com/quote/SBUX"> SBUX</a>) CEO Howard Schultz to let him open and operate multiple franchises in minority communities. Their first outlet opened on Crenshaw Boulevard in L.A., just a few blocks north of his theaters. According to the<a href="https://web.archive.org/web/20101020184051/https:/lakersblog.latimes.com/lakersblog/2010/10/magic-johnson-sells-his-starbucks-franchises.html"> Los Angeles Times</a>, Johnson eventually opened 125<a href="https://www.benzinga.com/insights/news/25/03/44377541/heres-how-much-1000-invested-in-starbucks-20-years-ago-would-be-worth-today"> Starbucks</a> outlets nationwide before selling 105 of them back to Starbucks for $100 million.&nbsp;
Johnson's investments and business deals are run through his company, Magic Johnson Enterprises, which he founded in 1987. Today, it's a multibillion-dollar operation with ownership stakes&nbsp; in the Los Angeles Dodgers and the NFL's Washington Commanders. Much of Johnson's early business success was built on his willingness to help himself by helping others.
Could incorporating Johnson's ethos into your<a href="https://www.benzinga.com/personal-finance/25/03/44440238/can-you-guess-how-much-you-need-to-build-generational-wealth-some-say-its-less-than-what-it-takes-to-feel-rich"> wealth-building strategy</a> yield similar results? You may not want to help rebuild an entire community, but having a larger sense of purpose can sharpen your focus. You can find your motivation anywhere. Once you do, working toward your goal will become a labor of love.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Personal Finance

Magic Johnson Is Worth Billions—But He Says You Can't Get There Thinking Only About Yourself

HubSpot's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) short percent of float has risen 35.62% since its last report. The company recently reported that it has 991 thousand shares sold short, which is 1.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>HubSpot Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743708628_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for HubSpot has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing HubSpot's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, HubSpot's peer group average for short interest as a percentage of float is 3.11%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

HUBS

Peering Into HubSpot's Recent Short Interest

IES Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NYSE">IESC</a>) short percent of float has fallen 3.42% since its last report. The company recently reported that it has 649 thousand shares sold short, which is 7.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.54 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>IES Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743708624_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for IES Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing IES Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, IES Hldgs's peer group average for short interest as a percentage of float is 5.74%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

IESC

Is IES Hldgs Gaining or Losing Market Support?

Archrock's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) short percent of float has fallen 24.41% since its last report. The company recently reported that it has 5.53 million shares sold short, which is 3.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Archrock Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743708618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Archrock has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Archrock's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Archrock's peer group average for short interest as a percentage of float is 8.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

AROC

What's Driving the Market Sentiment Around Archrock?

On Thursday, Goldman Sachs analyst Brooke Roach discussed the impact of the U.S. reciprocal tariffs on retail companies.
On April 2, President Trump announced reciprocal tariffs, including a 10% hike on all countries except Mexico and Canada, with higher rates for select nations with trade deficits.
The most significant retail impact is expected from increased tariffs on major sourcing partners like Vietnam, Indonesia, Bangladesh, and Cambodia, said the analyst.
The U.S. is significantly raising tariffs on imports, with China&#8217;s tariff rate increasing to 54% (up from 20%). Other key sourcing countries like Vietnam (46%), Indonesia (32%), Bangladesh (37%), Cambodia (49%), and India (27%) will also see tariff hikes, while EU imports face a 20% tariff.
Canada and Mexico remain exempt under USMCA, though non-USMCA compliant goods will be taxed at 12%. Overall, apparel and footwear tariffs are estimated to rise to an average of 38%, noted the analyst.
Additionally, the de minimis duty-free exemption for packages under $800 from China and Hong Kong will end on May 1, 2025.
These shipments will face a 30% tariff or $25 per item, increasing to $50 per item after June 1, 2025. The Secretary of Commerce will review within 90 days whether to expand this policy to Macau.
The newly announced tariffs will pressure brands and retailers, forcing them to adjust pricing, negotiate with vendors, and optimize costs to protect margins.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44630305/ai-powered-pizza-papa-johns-taps-google-cloud-for-smarter-orders" rel="noreferrer noopener">AI-Powered Pizza? Papa Johns Taps Google Cloud For Smarter Orders</a>
While most companies will be affected, some are less exposed, including brands with lower U.S. sales exposure like Amer Sports Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>), Canada Goose Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>) and PVH Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>). Retailers with indirect sourcing, such as department stores and off-price retailers, could benefit from supply chain disruptions.
Companies that do not source their product from international markets or source from exempt regions, such as Savers Value Village Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) with thrift business model and Kontoor Brands Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) reliance on Mexico, though it also sources from Bangladesh, are less exposed.
The analyst notes that brands with momentum and strong consumer engagement are likely to have more substantial relative pricing power in the marketplace overall.
The analyst noted higher exposure to incrementally new tariffs from Vietnam and Cambodia-exposed businesses include sportswear like Lululemon Athletica Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>), Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) and general apparel like Torrid Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>), Figs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>), Victoria&#8217;s Secret &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>), and Gap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>).
The Home Furnishings industry with companies like RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) and Williams-Sonoma Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) faces the greatest risk from tariffs due to its high exposure to China and Vietnam and the discretionary nature of its products.
RH sources 72% of its products from Asia, including 23% from China and 35% from Vietnam, while WSM has 23% China and 14% Vietnam exposure.
Retailers Five Below Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) and Best Buy Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) are also vulnerable, with 60% of their products sourced from China. While Vietnam exposure remains unclear for most industries, home furnishing companies have the highest risk, said the analyst.
On the other hand, Auto Parts companies like Advance Auto Parts Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>), AutoZone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) and O&#8217;Reilly Automotive Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) and Home Improvement retailers like Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) and Lowe&#8217;s Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) are better positioned, as they can pass increased costs.
Similarly, retailers that sell food like Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), BJ&#8217;s Wholesale Club Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>), and Costco Wholesale Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) are relatively insulated.
Companies with minimal reliance on China, such as Ulta Beauty Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) and Bath &amp; Body Works Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>), are also well-positioned against these tariffs.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44629352/rocket-lab-unveils-advanced-space-grade-radios-for-deep-space-missions" target="_blank" rel="noreferrer noopener">Rocket Lab Unveils Advanced Space-Grade Radios For Deep Space Missions</a></li>
</ul>
Image via Shutterstock.

BBWI

COST

CURV

FIGS

FIVE

GOOS

LULU

ORLY

ULTA

VSCO

Goldman Sachs Warns Tariffs Will Hit Apparel And Home Furnishings Hardest, Highlights Most Exposed Stocks

Guidance

STLA

Stellantis Says Because Of Engine Shortage, Company Will Idle Warren, Michigan Truck Assembly Plant For Several Weeks Starting April 14

Several restaurant stocks are taking a beating on Thursday as broader markets tumble in reaction to sweeping reciprocal tariffs from <a href="https://www.benzinga.com/news/global/25/04/44632479/retail-stocks-slammed-as-trumps-tariff-plan-sends-shockwaves-through-sector">the Trump administration</a>.
What Happened: President Donald Trump announced new tariffs on several countries across the world on Wednesday, sending markets into a tailspin.
Restaurant stocks are getting hit particularly hard as restaurant chains typically source food machinery and packaging from China. Trump announced 34% tariffs on China this week. 
According to a Wall Street Journal <a href="https://www.wsj.com/livecoverage/trump-tariffs-trade-war-stock-market-04-03-2025/card/restaurant-stocks-slide-on-trump-s-new-duties-IrOe9ndIoLz9heJhUlgk">report</a>, many restaurant chains buy potatoes from Canada and often import meats from other countries. 
Starbucks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) has significant exposure to China as the company operates thousands of stores in the country. Starbucks had a total of 7,685 stores in China as of the end of 2024. The company is also a big coffee importer. Shares were down more than 11% at last check, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Chipotle Mexican Grill Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) is also facing selling pressure as the company imports avocados from Mexico, Columbia and other countries globally. Chipotle shares were down about 3.5% at the time of writing.
Here&#8217;s a look at some other restaurant stocks moving lower Thursday:
<ul>
<li>Dutch Bros Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) down 9.05% at $56.24</li>
</ul>
<ul>
<li>Shake Shack Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) down 11.7% at $83.69</li>
</ul>
<ul>
<li>CAVA Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) down 7.49% at $83.01</li>
</ul>
<ul>
<li>Bloomin&#8217; Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) down 8.25% at $7.15</li>
</ul>
<ul>
<li>Cracker Barrel Old Country Store Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) down 13.5% at $35.48</li>
</ul>
<ul>
<li>Portillo&#8217;s Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) down 8.24% at $11.50</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44631713/tariffs-will-provide-great-buying-opportunity-in-long-term-investors-must-first-cross-stagflatio">Tariffs Will Provide Great Buying Opportunity In Long Term &#8211; Investors Must First Cross Stagflation Chasm</a></li>
</ul>
Photo: Shutterstock.

BLMN

BROS

CAVA

CBRL

PTLO

SBUX

SHAK

Restaurant Stocks Are Getting Cooked Thursday As Trump Tariffs Rattle Markets

WIIM

TMHC

Shares of homebuilders and housing-linked stocks are trading lower as markets react to President Trump's announcement of sweeping tariffs.

In March,&nbsp;Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
The company reported a patient death following treatment with Elevidys, having suffered <a target="_blank" href="https://www.benzinga.com/25/03/44376919/sarepta-therapeutics-reports-patient-death-post-elevidys-gene-therapy-treatment-stock-plunges" rel="noreferrer noopener">acute liver failure</a>.
Acute liver injury is a known possible side effect of Elevidys and other AAV-mediated gene therapies and is highlighted in the prescribing information.
On Wednesday, Sarepta and Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) temporarily <a target="_blank" href="https://www.duchenneuk.org/roche-temporarily-halts-clinic-studies/" rel="noreferrer noopener">halted</a> several clinical studies.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43232532/sarepta-therapeutics-duchenne-gene-therapy-shows-sustained-benefits-and-disease-stabilization-at-two-years" rel="noreferrer noopener">Sarepta Therapeutics&#8217; Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years</a>
Roche, the company to which the treatment is licensed outside the US, has said that this was at the European Medicines Agency&#8217;s (EMA) request.
The companies have a therapeutic clinical hold on Study 104, Study 302, and Study 303 in the EU until the analysis of the cause of death is complete.
Roche is also pausing the enrollment and dosing of participants in the U.K. for its ENVOL study.
Patient safety monitoring for already enrolled participants and ongoing collection of data will continue.
In June 2024, the EMA validated and <a target="_blank" href="https://www.roche.com/investors/updates/inv-update-2024-06-24" rel="noreferrer noopener">initiated</a> a review of the marketing authorization application for Elevidys, a gene therapy for ambulatory patients aged 3-7 years old with Duchenne muscular dystrophy.
HC Wainwright upgraded Sarepta on Wednesday from Sell to Neutral, saying it is trading within a fair range.
Analyst Mitchell S. Kapoor still anticipates Elevidys revenue will fall short in the second half of 2025—especially after the recent patient death due to acute liver injury.
Kapoor sees a risk that Elevidys sales may decline faster than expected, possibly as early as Q2 2025, due to growing hesitation from doctors and patients regarding its safety. The treatment&#8217;s limited effectiveness heightens this concern.
The analyst maintains the price <a target="_blank" href="https://www.benzinga.com/quote/SRPT/analyst-ratings" rel="noreferrer noopener">forecast of $75 per share</a>.
Needham maintained Sarepta Therapeutics with a Buy, lowering the price forecast from $202 to $183.
Price Action: SRPT stock is down 6.68% at $58.30 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44631273/novartis-secures-third-fda-approval-for-its-kidney-disease-portfolio-in-one-year" target="_blank" rel="noreferrer noopener">Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year</a></li>
</ul>
Image via Sarepta Therapeutics

Large Cap

RHHBY

SRPT

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

Goldman Sachs analyst Alexander Blostein expects macro and policy uncertainty, volatile equity markets, and declining short-term interest rates to weigh on EPS <a target="_blank" href="https://www.benzinga.com/topic/bank" rel="noreferrer noopener">forecasts for Capital Markets stocks</a>.
The analyst&#8217;s 2025 estimates are ~5% below consensus on average, except for Exchanges.
Blostein says Alternative Manager stocks face heightened EPS risks due to weaker realization activity (potential 30% downside to Street estimates) and a slower FRE growth trajectory, now expected to average 11% in 2025E,<a target="_blank" href="https://www.benzinga.com/quote/tpg/analyst-ratings" rel="noreferrer noopener"> down from ~15% previously</a>.
The analyst writes that Brookfield Asset Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) appears among the most resilient, <a target="_blank" href="https://www.benzinga.com/quote/bam/analyst-ratings" rel="noreferrer noopener">benefiting from index inclusion</a>.
While TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) and KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) offer attractive valuations, further EPS estimate revisions may be <a target="_blank" href="https://www.benzinga.com/quote/kkr/analyst-ratings" rel="noreferrer noopener">necessary, adds the analyst</a>.
On the other hand, the analyst says that the Brokers and Wealth Advisor stocks face an average 4%<a target="_blank" href="https://www.benzinga.com/quote/schw/analyst-ratings" rel="noreferrer noopener"> downside to 2025/2026 EPS estimates</a>.
Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) is performing better (+5% first-quarter EPS beat), while Stifel Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) is lagging <a target="_blank" href="https://www.benzinga.com/quote/sf/analyst-ratings" rel="noreferrer noopener">(-10% EPS miss), adds the analyst</a>.
Blostein expects lower short-term interest rates, weaker equity markets, and slower Investment Banking activity in 2025 to weigh on EPS, though he anticipates higher cash balances in March and stronger retail engagement to provide some relief.
Meanwhile, the analyst projects Traditional Managers to face ~5% EPS downside in 2025/26, with T. Rowe Price Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) and Janus Henderson Group plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) facing high-single-digits <a target="_blank" href="https://www.benzinga.com/quote/jhg/analyst-ratings" rel="noreferrer noopener">EPS risks in 2025/26.</a>
Blostein expects long-term average AUM to decline ~1% q/q, with <a target="_blank" href="https://www.benzinga.com/quote/trow/analyst-ratings" rel="noreferrer noopener">weaker second-quarter momentum</a>.
Fixed Income and Active ETFs show strength, but Active Equities outflows may drive a -2.0% annualized organic decline, adds the analyst.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44629640/us-services-sector-slows-sharply-as-hiring-drops-tariff-pressures-mount" target="_blank" rel="noreferrer noopener">US Services Sector Slows Sharply As Hiring Drops, Tariff Pressures Mount</a></li>
</ul>
Image via Shutterstock.

Mid Cap

Janus Henderson Group plc Ordinary Shares

SCHW

TROW

Goldman Sachs Sees Broad EPS Pressure Across Capital Markets, Highlights Brookfield As A Standout

Researchers investigated whether the shingles (herpes zoster) vaccine can help prevent dementia. Previous studies suggest that certain herpes viruses may contribute to dementia, and vaccines might have <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">immune benefits</a>.
The new research, published on Wednesday, Nature analyzed data from 282,541 older adults in Wales and found that people who received the original shingles live virus vaccine were 20% less likely to develop dementia than non-vaccinated participants.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44395415/trump-administration-weighs-deep-cuts-to-domestic-hiv-prevention-programs-gilead-stock-slides" rel="noreferrer noopener">Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides</a>
Shingles, also known as herpes zoster, is&nbsp;a painful rash illness caused by the varicella-zoster virus, the same virus that causes chickenpox, which reactivates in the body after a person has had chickenpox.
The <a target="_blank" href="https://www.nature.com/articles/s41586-025-08800-x#Sec4" rel="noreferrer noopener">study</a> found that getting the zoster vaccine lowered the chance of being diagnosed with dementia over seven years by 3.5 percentage points, or about 20% relative risk reduction.
The protective effect was stronger in women than men. The findings were confirmed in another population (England and Wales) using death certificate data, showing fewer dementia-related deaths among vaccinated individuals.
Previous research in July 2024 <a target="_blank" href="https://www.nature.com/articles/s41591-024-03201-5" rel="noreferrer noopener">hinted</a> that the older live shingles vaccine might offer some protection, but that vaccine has been discontinued in favor of the recombinant version.
Researchers found that people who received the recombinant vaccine had a 17% longer period without a dementia diagnosis—equal to about 164 extra days dementia-free for those who eventually developed the condition.
The recombinant vaccine also appeared to reduce dementia risk more than flu and tetanus–diphtheria–pertussis vaccines. The effect was seen in both men and women but was stronger in women.
Last year, GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) revealed data from the ZOSTER-049 long-term follow-up phase 3 trial, which followed participants for up to approximately 11 years following initial vaccination with Shingrix <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38289827/gsk-says-its-blockbuster-shingles-vaccine-shows-high-efficacy-even-after-10-years" rel="noreferrer noopener">(Recombinant Zoster Vaccine or RZV)</a>.&nbsp;
The final trial data demonstrate that RZV has maintained efficacy against shingles in adults over 50 for over a decade.&nbsp;
Shingrix sales for 2024 reached 3.36 billion pounds, down 2% (+1% at <a target="_blank" href="https://www.benzinga.com/25/02/43492835/gsk-launches-share-buyback-of-around-25-billion-after-better-than-expected-q4-earnings-raises-long-term-annual-sales-forecast-to-over-50-billion" rel="noreferrer noopener">constant currency)</a>.
Price Action: GSK stock is up 3.71% at $39.04 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44613813/sm-energy-to-see-q1-oil-output-rise-amid-uinta-expansion-says-analyst" target="_blank" rel="noreferrer noopener">SM Energy&#8217;s Near-Term Focus Centers On Debt Reduction Over Stock Buybacks: Analyst</a></li>
</ul>
Photo by HJBC via Shutterstock

Health Care

New Study Shows Shingles Vaccine Linked To 20% Lower Dementia Risk, GSK Stock Pops

AMRC

PRIM

SGBX

STRL

USLM

Shares of construction-related stocks are trading lower as markets react to President Trump's announcement of sweeping tariffs.

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has risen 16.85% since its last report. The company recently reported that it has 1.75 million shares sold short, which is 4.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.03 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743707727_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 4.79%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Molina Healthcare?

Press Releases

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Comments

Chemomab Therapeutics

Actualités

Dernières nouvelles pour Chemomab Therapeutics (NASDAQ:CMMB) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL